scholarly journals Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation

2011 ◽  
Vol 85 (12) ◽  
pp. 6060-6064 ◽  
Author(s):  
S. Xing ◽  
C. K. Bullen ◽  
N. S. Shroff ◽  
L. Shan ◽  
H.-C. Yang ◽  
...  
2011 ◽  
Vol 67 (2) ◽  
pp. 398-403 ◽  
Author(s):  
Sifei Xing ◽  
Shridhar Bhat ◽  
Neeta S. Shroff ◽  
Hao Zhang ◽  
Joseph A. Lopez ◽  
...  

2011 ◽  
Vol 139 (2) ◽  
pp. 142-154 ◽  
Author(s):  
Pierre-Alain Rubbo ◽  
Edouard Tuaillon ◽  
Karine Bolloré ◽  
Vincent Foulongne ◽  
Arnaud Bourdin ◽  
...  

2019 ◽  
Vol 16 (4) ◽  
pp. 302-314
Author(s):  
Chinnambedu Ravichandran Swathirajan ◽  
Ramachandran Vignesh ◽  
Greer Waldrop ◽  
Uma Shanmugasundaram ◽  
Pannerselvam Nandagopal ◽  
...  

Background:Anti-viral cytokine expressions by cytotoxic T-cells and lower activation rates have been reported to correlate with suppressed HIV replication in long-term non-progressors (LTNP). Immune mechanisms underlying disease non-progression in LTNP might vary with HIV-1 subtype and geographical locations.Objective:This study evaluates cytokine expression and T-cells activation in relation to disease non-progression in LTNP.Methods:HIV-1 Subtype C infected LTNP (n=20) and progressors (n=15) were enrolled and flowcytometry assays were performed to study HIV-specific CD8 T-cells expressing IL-2, IFN-γ, TNF-α and MIP-1β against gag and env peptides. CD4+ T-cell activation was evaluated by surface expression of HLADR and CD38.Results:Proportions of cytokines studied did not differ significantly between LTNP and progressors, while contrasting correlations with disease progression markers were observed in LTNP. CD4+ T-cell activation rates were significantly lower in LTNP compared to progressors which indicate the potential role of T-cell activation rates in disease non-progression in LTNP.Conclusion:LTNP and progressors showed similar CD8+ T-cell responses, but final conclusions can be drawn only by comparing multiple immune factors in larger LTNP cohort with HIV-1 infected individuals at various levels of disease progression. A possible role of HIV-1 subtype variation and ethnic differences in addition to host-genetic and viral factors cannot be ruled out.


AIDS ◽  
2012 ◽  
Vol 26 (7) ◽  
pp. 887-890 ◽  
Author(s):  
Elizabeth Hamlyn ◽  
Stephen Hickling ◽  
Kholoud Porter ◽  
John Frater ◽  
Rodney Phillips ◽  
...  

Author(s):  
Yanmeng Feng ◽  
Yifan Zhang ◽  
Zhangyufan He ◽  
Haojie Huang ◽  
Xiangxiang Tian ◽  
...  

Background It has been proven that inactivated COVID-19 vaccines are safe and effective in general population with intact immunity. However, their safety and immunogenicity have not been demonstrated in people living with HIV (PLWH). Methods 42 HIV-1 infected individuals who were stable on cART and 28 healthy individuals were enrolled in this study. Two doses of an inactivated COVID-19 vaccine (BIBP-CorV) were given 4 weeks apart. The safety and reactogenicity of the vaccine were evaluated by observing clinical adverse events and solicited local and systemic reactions. Humoral responses were measured by anti-spike IgG ELISA and surrogate neutralization assays. Cell-mediated immune responses and vaccine induced T cell activation were measured by flow cytometry. Findings All the HIV-1 infected participants had a CD4+ T cell count of above 200 cells/μL both at baseline and 4 weeks after vaccination. No solicited adverse reaction was observed among all participants. Similar binding antibody, neutralizing antibody and S protein specific T cell responses were elicited in PLWH and healthy individuals. Further analyses showed that PLWH with low baseline CD4+/CD8+ T cell ratios (<0.6) generated lower antibody responses after vaccination than PLWH with medium (0.6~1.0) or high (≥1.0) baseline CD4+/CD8+ T cell ratios (P<0.01). The CD3+, CD4+ and CD8+ T cell counts of PLWH decreased significantly after vaccination, but it did not lead to any adverse clinical manifestation. Moreover, we found that the general burden of HIV-1 among the PLWH cohort decreased significantly (P=0.0192) after vaccination. And the alteration of HIV-1 viral load was not significantly associated with the vaccine induced CD4+ T cell activation. Interpretation Our data demonstrate that the inactivated COVID-19 vaccine is safe and immunogenic in PLWH who are stable on cART with unsuppressed CD4 counts. Funding This work was funded by the National Natural Science Foundation of China (Grant No. 81971559, 82041010).


1994 ◽  
Vol 179 (1) ◽  
pp. 115-123 ◽  
Author(s):  
C A Spina ◽  
T J Kwoh ◽  
M Y Chowers ◽  
J C Guatelli ◽  
D D Richman

The viral regulatory gene, nef, is unique to the human immunodeficiency viruses (HIV) and their related primate lentiviruses. Expression of the nef gene has been shown to be essential to the maintenance of high levels of virus replication and the development of pathogenesis in the animal model of simian immunodeficiency virus (SIV) infection. In contrast to this in vivo model, the use of standard T cell culture systems to study nef function in vitro has produced a spectrum of contradictory results, and has failed to demonstrate a significant positive influence of nef on viral life cycle. We have developed a cell model to study regulation of HIV-1 replication that we believe reflects more accurately virus-cell interactions as they occur in vivo. Our experimental system used acute virus infection of purified, quiescent CD4 lymphocytes and subsequent induction of viral replication through T cell activation. With this cell model, NL4-3 virus clones with open and mutated nef reading frames were compared for replication competence. The clones with nef mutations showed reproducible and significant reductions in both rates of growth and maximal titers achieved. The degree of reduced replication was dependent on initial virus inoculum and the timing of T cell activation. The influence of nef was highly significant for induction of virus replication from a latent state within resting CD4 cells. Its effect was less apparent for virus infection of fully proliferating CD4 cells. This study demonstrates that nef confers a positive growth advantage to HIV-1 that becomes readily discernable in the primary cell setting of virus induction through T cell activation. The experimental cell model, which we describe here, provides not only a means to study nef function in vitro, but also provides important clues to the function of nef in HIV infection in vivo.


2019 ◽  
Vol 7 (18) ◽  
Author(s):  
Alexander K. Holbrook ◽  
Hunter D. Peterson ◽  
Samantha A. Bianchi ◽  
Brad W. Macdonald ◽  
Eric C. Bredahl ◽  
...  

2015 ◽  
Vol 45 (11) ◽  
pp. 3107-3113
Author(s):  
Kathrin Zimmermann ◽  
Sonia Bastidas ◽  
Leandra Knecht ◽  
Herbert Kuster ◽  
Stephan R. Vavricka ◽  
...  

2018 ◽  
Vol 34 (1) ◽  
pp. 103-110 ◽  
Author(s):  
Jamaluddin Md Saha ◽  
Hongbing Liu ◽  
Pei-Wen Hu ◽  
Bryan C. Nikolai ◽  
Hulin Wu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document